Vera Therapeutics (NASDAQ:VERA) Posts Earnings Results, Misses Estimates By $0.36 EPS

Vera Therapeutics (NASDAQ:VERA) posted its quarterly earnings results on Thursday. The company reported ($1.69) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.33) by ($0.36), Briefing.com reports. During the same quarter in the prior year, the business earned ($0.81) earnings per share.

Vera Therapeutics Price Performance

VERA stock opened at $35.88 on Friday. The stock has a 50-day moving average price of $39.96 and a two-hundred day moving average price of $40.35. The stock has a market cap of $2.56 billion, a PE ratio of -7.70 and a beta of 0.96. The company has a current ratio of 13.64, a quick ratio of 13.64 and a debt-to-equity ratio of 0.12. Vera Therapeutics has a 1 year low of $18.76 and a 1 year high of $56.05.

Insider Activity

In other Vera Therapeutics news, CFO Sean Grant sold 4,949 shares of the stock in a transaction dated Monday, February 23rd. The stock was sold at an average price of $41.98, for a total transaction of $207,759.02. Following the completion of the transaction, the chief financial officer owned 114,181 shares in the company, valued at approximately $4,793,318.38. This represents a 4.15% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, SVP Joseph R. Young sold 3,117 shares of the stock in a transaction dated Monday, February 23rd. The stock was sold at an average price of $41.98, for a total value of $130,851.66. Following the transaction, the senior vice president owned 64,722 shares of the company’s stock, valued at approximately $2,717,029.56. This trade represents a 4.59% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders have sold 56,441 shares of company stock worth $2,416,902. 15.90% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Vera Therapeutics

Several hedge funds have recently modified their holdings of the stock. Price T Rowe Associates Inc. MD grew its holdings in shares of Vera Therapeutics by 49.0% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 5,461,976 shares of the company’s stock valued at $276,595,000 after acquiring an additional 1,795,537 shares in the last quarter. Deerfield Management Company L.P. grew its holdings in shares of Vera Therapeutics by 8.8% in the 3rd quarter. Deerfield Management Company L.P. now owns 3,641,157 shares of the company’s stock valued at $105,812,000 after acquiring an additional 293,040 shares in the last quarter. Vestal Point Capital LP grew its holdings in shares of Vera Therapeutics by 24.0% in the 2nd quarter. Vestal Point Capital LP now owns 3,100,000 shares of the company’s stock valued at $73,036,000 after acquiring an additional 600,000 shares in the last quarter. State Street Corp grew its holdings in shares of Vera Therapeutics by 14.7% in the 4th quarter. State Street Corp now owns 2,676,600 shares of the company’s stock valued at $135,543,000 after acquiring an additional 343,017 shares in the last quarter. Finally, Integral Health Asset Management LLC grew its holdings in shares of Vera Therapeutics by 5.9% in the 4th quarter. Integral Health Asset Management LLC now owns 1,800,000 shares of the company’s stock valued at $91,152,000 after acquiring an additional 100,000 shares in the last quarter. Institutional investors own 99.21% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts have recently weighed in on VERA shares. Wolfe Research raised Vera Therapeutics from a “peer perform” rating to an “outperform” rating and set a $88.00 price target on the stock in a research note on Wednesday, March 11th. Weiss Ratings reissued a “sell (d-)” rating on shares of Vera Therapeutics in a research note on Monday, April 20th. Finally, HC Wainwright increased their price target on Vera Therapeutics from $90.00 to $110.00 and gave the company a “buy” rating in a research note on Monday, March 2nd. Ten research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $79.60.

About Vera Therapeutics

Vera Therapeutics is a clinical-stage biotechnology company focused on developing novel immunotherapies that harness the body’s own regulatory T cells to treat autoimmune and inflammatory diseases. By leveraging a proprietary protein engineering platform, the company designs Treg-selective cytokine variants intended to restore immune balance and provide targeted, disease-modifying effects. Its pipeline comprises multiple preclinical and clinical candidates aimed at indications characterized by chronic inflammation and autoimmunity.

Founded in 2018 and headquartered in Cambridge, Massachusetts, Vera Therapeutics collaborates with leading academic and research institutions to advance its development programs.